The Bioequivalence Study of Alfuzosin 10 mg Prolong-released Tablets Under Fed Conditions - Trial NCT06228339
Access comprehensive clinical trial information for NCT06228339 through Pure Global AI's free database. This Phase 1 trial is sponsored by International Bio service and is currently Not yet recruiting. The study focuses on Healthy Volunteer. Target enrollment is 44 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
International Bio service
Timeline & Enrollment
Phase 1
Mar 09, 2024
Mar 21, 2024
Primary Outcome
Plasma Area Under the Curve (AUC(0 to 48hr)) for Alfuzosin,Peak Plasma Concentration (Cmax) of Alfuzosin
Summary
Objective:
 
 Primary objective of the present study was to assess the relative bioavailability of
 Alfuzosin 10 mg Prolong-released Tablets under Fed conditions, in Healthy Thai Male
 Volunteers after an oral administration with 7 days washout period.
 
 Study Design:
 
 A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06228339
Non-Device Trial

